APPLIED STEMCELL

Company Snapshot

Founded: 2008
Entity Type: Private
Region: U.S.
Headquarter: California, U.S.
Key Geographics: U.S.
Corporate Address: 521 Cottonwood Dr. Suite #111 Milpitas, California 95035, U.S. Tel. +1-866-497-4180 www.appliedstemcell.com

Company Overview

Established in 2008, Applied StemCell is a biotechnology company with the mission of advancing gene-editing and stem cell innovation for biomedical research. The company offers a series of tools for basic research study, drug discovery, bioprocessing, bio-production, and preclinical applications.

The company is currently focusing on four areas:

  • Stem cell-based services and products to build next-generation cell line models and to advance cell-based therapies.
  • Physiologically predictive animal model generation and downstream in vivo assays for model validation and drug screening.
  • Gene-expression technology in cell lines for library screens, bio-production and bioassays.
  • Pre-IND enabling gene and cell therapy bio services CRO with service from model generation to efficacy/toxicology studies, potency assay, pre-IND filing, and chemistry, manufacturing, and controls (CMC) consultation. 

Using its proprietary TARGATT gene modification technology and its licensed CRISPR technology, the company generates site-specific knock-in rat, mouse, and human cell line models for the pharmaceutical and academic research communities.

The company offers a large array of products for site-specific transgenics, cell culture, and stem cell research. The company’s products encompass a broad spectrum, from high-quality transgenic kits for knock-in mice and knock-out mice generation, mouse embryonic fibroblast cells, feeder cells, growth factors, and options for stem cell characterization and stem cell differentiation, as well an array of iPSCs. The company offers iPSCs, iPSC-derived cells, reprogramming/ differentiation kits, and supplements, among many other products.

APPLIED STEMCELL In Reports

Induced Pluripotent Stem Cells: Global Markets

BCC Research Market Report says global market for induced pluripotent stem cells is expected to grow from $3.4 billion in 2023 and forecast to reach $5.2 billion by the end of 2028 at a CAGR of 9.1%.

Genome Editing: Technologies and Global Markets

Global genome editing market should reach $12.8 billion by 2027 from $4.3 billion in 2022 at a CAGR of 24.7% for the forecast period of 2022-27.

Induced Pluripotent Stem Cells: Global Markets

BCC Research Market Report says induced pluripotent stem cells should grow from $2.8 billion in 2021 to $4.4 billion by 2026, at compound annual growth rate of 9.3%.

Company's Business Segments

  • Stem Cell Products : GMP Grade iPSCs, iPSC Lines, iPSC Differentiated Cell Products, MEF Feeder Cells, Primary Cells and Tissues.
  • Stem Cell Services : iPSC Gene Editing, iPSC Differentiation Cell Services, iPSC Generation Services, Cell-Based Assays.
  • CRO/CDMO : cGMP Cell Manufacturing and Cell Banking, GMP Plasmid Manufacturing, Process and Analytical Development, Quality Management & Regulatory.
  • Tissue Samples and Primary Cells : Humanized Mouse Models | Off-the-shelf, Teratoma Formation, CAR-T/NK and Biologics Efficacy Studies, Biodistribution, PD and PK Studies.

Applications/End User Industries

  • Biomedical Research
  • Biotechnology Industry
AI Sentiment